Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells
Context Therapeutic benefits of immunotherapy are restricted by cancer immune-resistance mechanisms. Rediocide-A (Red-A), a natural product extracted from Traditional Chinese Medicine, is a promising agent to battle against cancer which acts as an immune checkpoint inhibitor. Objective To investigat...
Main Authors: | Wanyi Ng, Chenyuan Gong, Xuewei Yan, Guifan Si, Chen Fang, Lixin Wang, Xiaowen Zhu, Zihang Xu, Chao Yao, Shiguo Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/13880209.2020.1865410 |
Similar Items
-
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
by: Minjeong Yeon, et al.
Published: (2020-06-01) -
Immuno-Oncology Medicines: Policy Implications and Economic Considerations
by: Georges Adunlin, et al.
Published: (2019-08-01) -
Immunodynamics of explanted human tumors for immuno‐oncology
by: Agathe Dubuisson, et al.
Published: (2021-01-01) -
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
by: Nayoung Kim, et al.
Published: (2018-09-01) -
Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
by: Ye Li, et al.
Published: (2021-06-01)